Myriad

Myriad Genetics’ Strategic Growth Fuels Bullish Outlook (NASDAQ:MYGN)

admin4 months ago017 mins

Yozayo In the field of genetic testing and precision medicine, Myriad Genetics (NASDAQ: NASDAQ:MYGN) is a progressive company, which can be observed in its steady double-digit revenue growth and the upward revision of revenue guidance for the next year. The financial results of the third quarter of 2023 of the company demonstrate a strong year-over-year…

Myriad Genetics, Inc. (MYGN) Q3 2023 Earnings Call Transcript

admin6 months ago063 mins

Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Matt Scalo – Senior Vice President, Investor Relations Paul Diaz – President and Chief Executive Officer Mark Verratti – Chief Commercial Officer Bryan Riggsbee – Chief Financial Officer Conference Call Participants Elizabeth Koslosky – Goldman Sachs Andrew Cooper…

Two High Quality 8-9% Yielding Stocks Worth Considering (NYSE:BSM)

Federal Reserve Watch: Plenty Of Money Still Around

Iran’s President Ebrahim Raisi dead in helicopter crash

Aby Rosen was New York real estate royalty. Is his office empire crumbling?

Toyota: A Profit-Growth Pause No Reason For Concern (NYSE:TM)

April Retail Sales Down And Stocks Sold Off, I See Opportunities

Myriad Genetics’ Strategic Growth Fuels Bullish Outlook (NASDAQ:MYGN)

Myriad Genetics, Inc. (MYGN) Q3 2023 Earnings Call Transcript